435 related articles for article (PubMed ID: 15909291)
1. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
2. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
Gönen M
Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
[TBL] [Abstract][Full Text] [Related]
4. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding approach for dose escalation with overdose control considering incomplete observations.
Mauguen A; Le Deley MC; Zohar S
Stat Med; 2011 Jun; 30(13):1584-94. PubMed ID: 21351289
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Tighiouart M; Cook-Wiens G; Rogatko A
J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
[TBL] [Abstract][Full Text] [Related]
7. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
8. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
Wang M; Day R
J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
[TBL] [Abstract][Full Text] [Related]
9. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
10. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
11. An optimization algorithm for designing phase I cancer clinical trials.
Jiang H; Liu Y; Su Z
Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
[TBL] [Abstract][Full Text] [Related]
12. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
13. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
Morita S
Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
[TBL] [Abstract][Full Text] [Related]
14. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.
Cheng JD; Babb JS; Langer C; Aamdal S; Robert F; Engelhardt LR; Fernberg O; Schiller J; Forsberg G; Alpaugh RK; Weiner LM; Rogatko A
J Clin Oncol; 2004 Feb; 22(4):602-9. PubMed ID: 14966084
[TBL] [Abstract][Full Text] [Related]
15. Dose-escalation designs in oncology: ADEPT and the CRM.
Shu J; O'Quigley J
Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
[TBL] [Abstract][Full Text] [Related]
16. Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit.
Whitehead J; Zhou Y; Stevens J; Blakey G; Price J; Leadbetter J
Stat Med; 2006 Jan; 25(1):37-53. PubMed ID: 16342336
[TBL] [Abstract][Full Text] [Related]
17. A two-stage dose selection strategy in phase I trials with wide dose ranges.
Wang O; Faries DE
J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
19. Simultaneously optimizing dose and schedule of a new cytotoxic agent.
Braun TM; Thall PF; Nguyen H; de Lima M
Clin Trials; 2007; 4(2):113-24. PubMed ID: 17456511
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
